Skip Navigation
 

Funding


RCDC

Project Listing by Category


Back to Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC) Click the column headings to sort project listings.
  Help
CategoryFYFunding ICProject NumberSub Project #Project TitlePI NameOrg NameState / CountryAmount
Uterine Cancer 2018 NCI 5R01CA193455-03 NCOA6, A Novel Tumor Suppressor of Endometrial Cancer XU, JIANMING BAYLOR COLLEGE OF MEDICINE TX $86,504
Uterine Cancer 2018 NCI 5R01CA183953-04 Cerenkov luminescence imaging for image-guided cancer surgery GRIMM, JAN SLOAN-KETTERING INST CAN RESEARCH NY $488,147
Uterine Cancer 2018 NCI 5R01CA119171-11 Nutrition and Physical Activity Assessment Study (NPAAS) NEUHOUSER, MARIAN FRED HUTCHINSON CANCER RESEARCH CENTER WA $791,418
Uterine Cancer 2018 NCI 5R01CA183877-04 Pathobiology and Mechanism of Progesterone Resistance in Human Endometrial Cancer MEMARZADEH, SANAZ UNIVERSITY OF CALIFORNIA LOS ANGELES CA $352,275
Uterine Cancer 2018 NCCIH 5R01AT008824-03 Botanical derived progestins and their impact on women's health BURDETTE, JOANNA UNIVERSITY OF ILLINOIS AT CHICAGO IL $359,775
Uterine Cancer 2018 NCI 5R01CA211339-02 Next-Generation Mouse Models of Endometrial Cancer CASTRILLON, DIEGO UT SOUTHWESTERN MEDICAL CENTER TX $570,932
Uterine Cancer 2018 NCI 5R01CA175486-05 Systematic Functional Characterization of RNA Editing in Endometrial Cancer LIANG, HAN UNIVERSITY OF TX MD ANDERSON CAN CTR TX $332,000
Uterine Cancer 2018 NCI 5R01CA196912-03 Novel tumorigenic mechanisms of the LKB1 tumor suppressor CASTRILLON, DIEGO UT SOUTHWESTERN MEDICAL CENTER TX $370,575
Uterine Cancer 2018 NCI 5U10CA180868-05 NRG ONCOLOGY NETWORK GROUP OPERATIONS CENTER WOLMARK, NORMAN NRG ONCOLOGY FOUNDATION, INC. PA $12,282,049
Uterine Cancer 2018 NCI 5R01CA216103-02 Molecular Mechanisms Underlying Environmental Effects that Influence Penetrance in Lynch Syndrome-Associated Endometrial Cancer YATES, MELINDA UNIVERSITY OF TX MD ANDERSON CAN CTR TX $288,000
Uterine Cancer 2018 NCI 5R01CA207240-02 Phase I trial of intravenous vesicular stomatitis virus for treatment of metastatic endometrial cancer BAKKUM-GAMEZ, JAMIE MAYO CLINIC ROCHESTER MN $543,708
Uterine Cancer 2018 NCI 5U01CA176067-05 Integrated genomic analysis of racial disparities in endometrial cancer SANTIN, ALESSANDRO YALE UNIVERSITY CT $347,588
Uterine Cancer 2018 NCI 5R01CA196975-03 First in-human PET imaging studies of NIS reporter [18F]BF4 DEGRADO, TIMOTHY MAYO CLINIC ROCHESTER MN $172,718
Uterine Cancer 2018 NCI 5R01CA200864-03 Molecular Classification of High Grade Endometrial Cancers: Extending TCGA Findings to a Diverse Population COTE, MICHELE WAYNE STATE UNIVERSITY MI $597,672
Uterine Cancer 2018 NCI 1R37CA226969-01 Obesity-driven Metabolic and Molecular Biomarkers of Metformin Response in Endometrial Cancer BAE-JUMP, VICTORIA UNIV OF NORTH CAROLINA CHAPEL HILL NC $355,706
Uterine Cancer 2018 NCI 5P30CA091842-17 6318 Solid Tumor Therapeutics (Project-007) EBERLEIN, TIMOTHY WASHINGTON UNIVERSITY MO $94,890
Uterine Cancer 2018 NCI 5T32CA101642-13 Training of Academic Gynecologic Oncologists LU, KAREN UNIVERSITY OF TX MD ANDERSON CAN CTR TX $467,856
Uterine Cancer 2018 NICHD 5R01HD042311-15 Molecular Analysis of Uterine Receptivity LYDON, JOHN BAYLOR COLLEGE OF MEDICINE TX $328,888
Uterine Cancer 2018 NCI 1K01CA218457-01A1 Effect of adiposity changes on endometrial tissue and blood biomarkers in women at increased risk for endometrial cancer FELIX, ASHLEY OHIO STATE UNIVERSITY OH $133,625
Uterine Cancer 2018 NCI 5R01CA176502-05 Stabilizing nuclear p27kip1 as a therapeutic target for endometrial cancer GOLD, LESLIE NEW YORK UNIVERSITY SCHOOL OF MEDICINE NY $581,460
Uterine Cancer 2018 NCI 5R01CA218287-02 Signature-guided therapy for mismatch repair defective cancers LIN, SHIAW-YIH UNIVERSITY OF TX MD ANDERSON CAN CTR TX $373,331
Uterine Cancer 2018 NCI 5R03CA212808-02 A pooled analysis of dietary long-chain omega-3 fatty acid intake and endometrial cancer risk BRASKY, THEODORE OHIO STATE UNIVERSITY OH $78,000
Uterine Cancer 2018 NCI 5T32CA060396-23 Gynecologic Oncology Fellowship Program DISAIA, PHILIP UNIVERSITY OF CALIFORNIA-IRVINE CA $194,283
Uterine Cancer 2018 NCI 5R01CA172279-05 Novel epigenetic paradigm in endometrial cancer recurrence HUANG, TIM UNIVERSITY OF TEXAS HLTH SCIENCE CENTER TX $308,364
Uterine Cancer 2018 NCI 5R01CA192438-05 Epidemiology of the four most frequent cancers following breast cancer MALONE, KATHLEEN FRED HUTCHINSON CANCER RESEARCH CENTER WA $928,970
Uterine Cancer 2018 NCI 5R01CA194496-03 Molecular Mechanisms and Applications of Novel ER/GPER-selective Ligands PROSSNITZ, ERIC UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR NM $320,000
Uterine Cancer 2018 NCI 5R01CA184101-05 MTDH regulates Fanconi anemia repair pathway to mediate drug resistance MENG, XIANGBING UNIVERSITY OF IOWA IA $313,622
Uterine Cancer 2018 NCI 5P50CA098258-13 8325 Administrative Core LU, KAREN UNIVERSITY OF TX MD ANDERSON CAN CTR TX $262,959
Uterine Cancer 2018 NCI 5P50CA098258-13 8326 Pathology Core BROADDUS, RUSSELL UNIVERSITY OF TX MD ANDERSON CAN CTR TX $179,697
Uterine Cancer 2018 NCI 5P50CA098258-13 8327 Biomarkers Core LOOSE, DAVID UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON TX $28,471
Uterine Cancer 2018 NCI 5P50CA098258-13 8328 Biostatistics and Bioinformatics Core YUAN, YING UNIVERSITY OF TX MD ANDERSON CAN CTR TX $179,696
Uterine Cancer 2018 NCI 5P50CA098258-13 8329 Developmental Research Program BURKE, THOMAS UNIVERSITY OF TX MD ANDERSON CAN CTR TX $139,697
Uterine Cancer 2018 NCI 5P50CA098258-13 8330 Career Enhancement Program BODURKA, DIANE UNIVERSITY OF TX MD ANDERSON CAN CTR TX $139,698
Uterine Cancer 2018 NCI 5P50CA098258-13 8331 P1: Novel Targeted Strategies for Prevention and Conservative Management of Complex Atypical Hyperplasia and Grade 1 Endometrioid Endometrial Cancer LU, KAREN UNIVERSITY OF TX MD ANDERSON CAN CTR TX $291,695
Uterine Cancer 2018 NCI 5P50CA098258-13 8332 P2: CTNNB1 Mutation and Wnt Pathway Activation Define Clinically Aggressive Endometrioid Endometrial Carcinoma BROADDUS, RUSSELL UNIVERSITY OF TX MD ANDERSON CAN CTR TX $291,693
Uterine Cancer 2018 NCI 5P50CA098258-13 8333 P3: EphA2 Targeting in Uterine Carcinoma SOOD, ANIL UNIVERSITY OF TX MD ANDERSON CAN CTR TX $291,692
Uterine Cancer 2018 NCI 5P50CA098258-13 8334 P4: A Framework for Identification of Novel Targeted Therapy Combinations in Endometrial Cancer MILLS, GORDON UNIVERSITY OF TX MD ANDERSON CAN CTR TX $291,693
Uterine Cancer 2018 NCI 5P50CA098258-13 7324 Molecular Modifiers of Endometrial Endometrioid Adenocarcinoma Immune Microenvironment: Impact of PTEN loss and CD73-Generated Adenosine Loss BROADDUS, RUSSELL UNIVERSITY OF TX MD ANDERSON CAN CTR TX $171,701
Uterine Cancer 2018 NCI 5R21CA220269-02 Inter-relationship between microbiota diversity, obesity and race in endometrial cancer BAE-JUMP, VICTORIA UNIV OF NORTH CAROLINA CHAPEL HILL NC $169,106
Uterine Cancer 2018 NIGMS 2P20GM103639-06A1 6148 Exosomes in Predicting Response to Chemotherapy in Metastatic Endometrial Carcinoma MOXLEY, KATHERINE UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR OK $217,500
Uterine Cancer 2018 NIA 2R01AG028084-11 Variations in Hormones During Menopause: Effects on Cognitive and Brain Aging BIMONTE-NELSON, HEATHER ARIZONA STATE UNIVERSITY-TEMPE CAMPUS AZ $322,586
Uterine Cancer 2018 NCI 1R01CA223219-01A1 Combined NGS tumor-based detection of germline Lynch syndrome mutations and prognostic classification of endometrial cancers GOODFELLOW, PAUL OHIO STATE UNIVERSITY OH $531,474
Uterine Cancer 2018 NCI 5F32CA221007-02 The role of mRNA methylation in the progression of endometrial cancer HARADA, BRYAN UNIVERSITY OF CHICAGO IL $59,038
Uterine Cancer 2018 NCI 1F30CA224979-01A1 Defining the role of endometrial cancer PP2A A-alpha mutations in tumorigenesis TAYLOR, SARAH CASE WESTERN RESERVE UNIVERSITY OH $44,524
Uterine Cancer 2018 NCI 1K08CA234333-01 Obstetrical and Oncological Outcomes Among Reproductive Age Women with Gynecological and Breast Cancer RAUH-HAIN, JOSE UNIVERSITY OF TX MD ANDERSON CAN CTR TX $250,514
Uterine Cancer 2018 NCI 261200800001E-132-0-35 Genotyping for epidemiology studies HEIMBROOK, DAVID LEIDOS BIOMEDICAL RESEARCH, INC. MD $5,300,000
Uterine Cancer 2018 NCI 261200800001E-132-0-36 Repository Services for epidemiology studies HEIMBROOK, DAVID LEIDOS BIOMEDICAL RESEARCH, INC. MD $2,735,000
Uterine Cancer 2018 NCI 3U10CA180868-05S1 NRG ONCOLOGY NETWORK GROUP OPERATIONS CENTER WOLMARK, NORMAN NRG ONCOLOGY FOUNDATION, INC. PA $745,015
Uterine Cancer 2018 NCI 1R41CA232867-01A1 Robust Predictor of Colon Cancer Risk OSTRER, HARRY MORGAN AND MENDEL GENOMICS, INC. DE $300,000
Uterine Cancer 2018 NCI 4R00CA218694-02 Blood metabolite profiles and risk of developing endometrial cancer PLAYDON, MARY UNIVERSITY OF UTAH UT $249,000
Uterine Cancer 2018 NCI 1R21CA239457-01 Impact of hurricane-related stressors and responses on oncology care and health outcomes of women with gynecologic cancers from Puerto Rico and US Virgin Islands ORTIZ, ANA COMPREHENSIVE CANCER CENTER/ UNIV/PR PR $193,813
Uterine Cancer 2018 NCI 4K00CA212222-03 Inflammation and gynecologic cancer: the role of prostaglandins in ovarian cancer BARNARD, MOLLIE UNIVERSITY OF UTAH UT $88,280
Uterine Cancer 2018 NCI 3P30CA091842-17S1 6318 Solid Tumor Therapeutics (Project-007) EBERLEIN, TIMOTHY WASHINGTON UNIVERSITY MO $12,044
Uterine Cancer 2018 NCI 3P30CA091842-17S2 6318 Solid Tumor Therapeutics (Project-007) EBERLEIN, TIMOTHY WASHINGTON UNIVERSITY MO $11,082
Uterine Cancer 2018 NCI 3P30CA043703-28S2 Contribution of Gynecologic and Breast Cancer Biospecimens from African American women to HCMI GERSON, STANTON CASE WESTERN RESERVE UNIVERSITY OH $48,000
Uterine Cancer 2018 NCI 3P30CA091842-17S3 6318 Solid Tumor Therapeutics (Project-007) EBERLEIN, TIMOTHY WASHINGTON UNIVERSITY MO $8,695
Uterine Cancer 2018 NCI 3P30CA091842-17S4 6318 Solid Tumor Therapeutics (Project-007) EBERLEIN, TIMOTHY WASHINGTON UNIVERSITY MO $5,424
Uterine Cancer 2018 NCI 3R44CA221398-01S1 Clinical Efficacy Evaluation of First-in-class Imipridone ONC201 in Recurrent Type II Endometrial Cancer OSTER, WOLFGANG ONCOCEUTICS, INC. PA $4,319
Uterine Cancer 2018 NCI 3P50CA098258-13S1 8325 Administrative Core LU, KAREN UNIVERSITY OF TX MD ANDERSON CAN CTR TX $17,456
Uterine Cancer 2018 NCI 3P50CA098258-13S1 8326 Pathology Core BROADDUS, RUSSELL UNIVERSITY OF TX MD ANDERSON CAN CTR TX $17,455
Uterine Cancer 2018 NCI 3P50CA098258-13S1 8327 Biomarkers Core LOOSE, DAVID UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON TX $17,455
Uterine Cancer 2018 NCI 3P50CA098258-13S1 8328 Biostatistics and Bioinformatics Core YUAN, YING UNIVERSITY OF TX MD ANDERSON CAN CTR TX $17,455
Uterine Cancer 2018 NCI 3P50CA098258-13S1 8329 Developmental Research Program BURKE, THOMAS UNIVERSITY OF TX MD ANDERSON CAN CTR TX $17,455
Uterine Cancer 2018 NCI 3P50CA098258-13S1 8330 Career Enhancement Program BODURKA, DIANE UNIVERSITY OF TX MD ANDERSON CAN CTR TX $17,454
Uterine Cancer 2018 NCI 3P50CA098258-13S1 8331 P1: Novel Targeted Strategies for Prevention and Conservative Management of Complex Atypical Hyperplasia and Grade 1 Endometrioid Endometrial Cancer LU, KAREN UNIVERSITY OF TX MD ANDERSON CAN CTR TX $17,454
Uterine Cancer 2018 NCI 3P50CA098258-13S1 8332 P2: CTNNB1 Mutation and Wnt Pathway Activation Define Clinically Aggressive Endometrioid Endometrial Carcinoma BROADDUS, RUSSELL UNIVERSITY OF TX MD ANDERSON CAN CTR TX $17,454
Uterine Cancer 2018 NCI 3P50CA098258-13S1 8333 P3: EphA2 Targeting in Uterine Carcinoma SOOD, ANIL UNIVERSITY OF TX MD ANDERSON CAN CTR TX $17,454
Uterine Cancer 2018 NCI 3P50CA098258-13S1 8334 P4: A Framework for Identification of Novel Targeted Therapy Combinations in Endometrial Cancer MILLS, GORDON UNIVERSITY OF TX MD ANDERSON CAN CTR TX $17,454
Uterine Cancer 2018 NCI 3P50CA098258-13S1 7324 Molecular Modifiers of Endometrial Endometrioid Adenocarcinoma Immune Microenvironment: Impact of PTEN loss and CD73-Generated Adenosine Loss BROADDUS, RUSSELL UNIVERSITY OF TX MD ANDERSON CAN CTR TX $17,454
Uterine Cancer 2018 NCI 3UM1CA173642-05S3 Women's Health Initiative Cancer Survivor Cohort ANDERSON, GARNET FRED HUTCHINSON CANCER RESEARCH CENTER WA $175,562
Uterine Cancer 2018 NCI 4R44CA221398-02 Clinical Efficacy Evaluation of First-in-class Imipridone ONC201 in Recurrent Type II Endometrial Cancer OSTER, WOLFGANG ONCOCEUTICS, INC. PA $714,000
Uterine Cancer 2018 NCI 1ZIACP010126-23 Hormone-Related Cancers GIERACH, GRETCHEN NIH $2,799,580
Uterine Cancer 2018 NCI 1ZIACP010128-23 Therapeutic and Diagnostic Factors as Related to Cancer Risk TRABERT, BRITTON NIH $487,300
Uterine Cancer 2018 NCI 1ZIACP010182-16 Epidemiologic Field Studies SCHAIRER, CATHERINE NIH $1,284,187
Uterine Cancer 2018 NCI 1ZIACP010187-14 Cancer Genetic Markers of Susceptibility HOOVER, ROBERT NIH $252,996
Uterine Cancer 2018 NIEHS 1ZIAES102405-11 Environmental influence on reproductive tract function WILLIAMS, CARMEN NIH $1,083,776
Uterine Cancer 2018 NCI 261201200033I-2-26100011-1 PILOT STUDY OF DAILY EXEMESTANE IN WOMEN WITH COMPLEX ATYPICAL HYPERPLASIA OF THE ENDOMETRIUM/ENDOMETRIAL INTRAEPITHELIAL NEOPLASIA OR GRADE 1 ENDOMETRIAL CANCER BAILEY, HOWARD UNIVERSITY OF WISCONSIN-MADISON WI $280,420
Uterine Cancer 2018 NCI 1ZIABC005177-38 Interaction of Chemical Carcinogens and Chemotherapeutic Agents with DNA POIRIER, MIRIAM NIH $50,092
Uterine Cancer 2018 NIMHD 1ZIJMD000009-02 Dr. William Coleman Award NAPOLES, ANNA NIH $105,144
Uterine Cancer 2018 NHGRI 1ZIAHG200323-14 Regulatory and epigenetic landscapes in biological discovery, diagnostics and disease mechanisms ELNITSKI, LAURA NIH $1,792,057
Uterine Cancer 2018 NHGRI 1ZIAHG200330-14 Comparative Genomics Analysis Unit Research MULLIKIN, JAMES NIH $1,236,149
Uterine Cancer 2018 NHGRI 1ZIAHG200338-12 Genomic Analyses of Endometrial Cancer BELL, DAPHNE NIH $1,225,201
Uterine Cancer 2018 NHGRI 1ZIAHG200379-07 Identification of genetic alterations that underlie endometrial carcinosarcomas BELL, DAPHNE NIH $29,086


  • Download Readers:
  • Download Adobe PDF Reader
  • Download Microsoft PowerPoint Viewer
  • Download Microsoft Word Viewer
  • Download Microsoft Excel Viewer